Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with Initial Cohort Data Expected in Mid-2024 VANCOUVER,… Read More
PhytoSquene® now available for clinical and commercial use Adjuvant component for parenteral drug delivery applications Provides batch-to-batch consistency, quality and purity and reduces reliance on animal-derived materials Evonik’s non-animal-derived squalene… Read More
VANCOUVER, BC, TORONTO, ON, and MONTREAL, QC — adMare BioInnovations is proud to launch the enhanced adMare Community, a revamped online platform with several new, more advanced and efficient features, dedicated… Read More
Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy Enfortumab vedotin plus pembrolizumab improved median overall survival by more than 15… Read More
TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress Results from innovaTV 301 intended to serve as… Read More
